TMO stock news · Thermo Fisher Scientific
Get alerts for TMO
Follow Thermo Fisher Scientific (TMO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TMOLisa P. Britt, the HR Chief at Thermo Fisher Scientific, sold 2,831 shares for almost $2 million.
NeutralThermo Fisher Chief HR Officer Lisa Britt sold 2,831 shares and still owns 11,559. The filing gives no news about company operations, so it does not change the business outlook.
Thermo Fisher Scientific said Executive Vice President Michael D. Shafer will retire on December 31, 2026.
NeutralThermo Fisher said executive vice president Michael D. Shafer will retire on December 31, 2026.
Citi keeps its "Buy" recommendation and bumps up the price target for Thermo Fisher Scientific to $800.
Good for TMOCiti kept its Buy rating on Thermo Fisher and raised its price target to $800. That is a positive analyst view, not new proof of company growth.
Citi says to keep buying Thermo Fisher Scientific and has increased its price goal to $800.
Good for TMOCiti kept its Buy rating on Thermo Fisher and raised its price goal to $800. That signals a more favorable analyst view, though the story reports no new company results.
Rothschild & Co Redburn raises its price goal for Thermo Fisher Scientific from $725 to $750.
Good for TMOThermo Fisher's analyst price target rose, adding a favorable signal for TMO. FactSet also reports a favorable average rating, but this is analyst opinion, not a company result.
Experts change their price predictions for Thermo Fisher Scientific.
Good for TMOSeveral firms raised their Thermo Fisher price targets, signaling stronger analyst confidence. This is a positive sign, though it is opinion rather than new business results.
Thermo Fisher Scientific Inc. shared its financial results for the quarter ending September 26, 2026.
NeutralThermo Fisher announced quarterly results, but this filing gives no sales or profit figures. It does not show whether the quarter helped or hurt the company.
Big investors are making moves with 9 health care stocks today.
NeutralThermo Fisher was listed with a put trade labeled bullish. This reports options activity, not a change in the company’s business, so it does not change its outlook.
Thermo Fisher will help Quantum Biopharma test a new drug for multiple sclerosis.
NeutralThermo Fisher's research unit will provide study-startup and related trial services for Quantum BioPharma. The story gives no contract value or wider business effect, so it does not change the outlook for Thermo Fisher.
India ranks among the fastest-expanding markets for Thermo Fisher.
Good for TMOThermo Fisher Scientific has announced that India is one of its fastest-growing markets, with expectations of a 15% to 20% growth in its customer base over the next five years. This growth is attributed to the expanding biopharmaceutical research and manufacturing industry in India, which is expected to drive demand for the company's products.